Anthropic's Foray into Drug Design Sparks Heated Debate
PatrickKidger · x · 2026-07-05
Anthropic's entry into drug design (AIxBio) has sparked controversy within the biopharma community. Pessimists question the move, citing that "drug design is hard," "they shouldn't compete with customers," and that "if they really want to do it, they should acquire Cradle or Boltz." ML researcher Patrick Kidger publicly countered these views, stating that despite Anthropic starting behind the AIxBio SOTA and needing to tackle difficult coursework, he is still excited by capable people stepping up to solve these problems, believing it could be the start of something remarkable.
More from Companies & People
- Fmr. OpenAI Design Head Ian Silber, Who Led ChatGPT and Codex, to Speak at SPC — soleio · 2026-10-26
- Anthropic files S-1 with SEC, formally kicking off its IPO process — minchoi · 2026-10-26
- Silicon Valley breakdown: five Stanford-area giants worth ~$18T — FinanceYF5 · 2026-10-26
- User suspects X's bundled Grok subscription boosted tweet reach amid algorithm change rumors — talkaboutdesign · 2026-10-26
- "RIP Claude + Chrome": developer flags the end of Anthropic's browser integration — damienghader · 2026-10-26
- a16z podcast: Diode pairs AI PCB design with Brooklyn factory to revive US hardware manufacturing — MattPerault · 2026-10-26